SummaryCAID syndrome is a genetic disease in which failure of pacemakers in the entire human body leads to loss of all bowel movements. We here identify unknown mechanisms by which CAID syndrome causes this intestinal disease.

Lifelong rhythmic contractions are the hallmark of the human heart and gut. Both organs contain pacemaker cells that spontaneously can generate an action potential through a shared polarization mechanism involving ion channels. In the heart, the sinoatrial node is responsible for this mechanism, whereas in the gut, the network of interstitial cells of Cajal and the autonomous enteric nervous system depolarize the myocytes and allow the induction of electric signals.

Disorders of pacemaking are a major cause of gastrointestinal and cardiac diseases. Chronic intestinal pseudo-obstruction (CIPO) is a rare and severe disorder of gastrointestinal motility in which intestinal obstruction occurs in the absence of a mechanical obstacle. CIPO is one of the most important causes of intestinal insufficiency in pediatric (15%) and adult cases (20%).[@bib1], [@bib2], [@bib3] CIPO can result from the insufficiency of pacemaker cells and the enteric nervous system to generate or propagate electric signals and stimulate subsequent contraction of the smooth muscles, leading to contraction defects (neurogenic CIPO). It also can result from primary smooth muscle contraction defects (myogenic CIPO). CIPO is a devastating and life-long disease that often requires surgical intestinal decompression as well as total parenteral nutrition. Even though X-linked, autosomal-dominant, and recessive mutations have been identified in *FLNA*, *ACTG2*, *TYMP*, *POLG1*, and *RAD21*, most cases are sporadic and leave the causes and pathomechanisms of CIPO poorly defined.[@bib4], [@bib5], [@bib6], [@bib7], [@bib8]

We recently identified a generalized human pacemaking syndrome, encompassing both gastrointestinal and cardiac dysrhythmias. We have termed this condition *chronic atrial and intestinal dysrhythmia* (CAID) *syndrome* (OMIM 616201). We identified a recessive point mutation in the cohesion regulator *SGO1*, namely K23E, as the cause of CAID syndrome.[@bib3] CAID patients appeared normal at birth, and no patient had any other congenital anomalies. Gastrointestinal symptoms usually preceded cardiac symptoms. In different individuals with CAID, CIPO was found to be of neurogenic, myogenic, or mixed origin.[@bib3] Representative manometries of CAID patients showed visceral neuropathy with abnormal response to intravenous erythromycin and colonic manometries showed visceral myopathy with low-amplitude propagated contractions after stimulation.[@bib3] Gastrointestinal symptoms were also the main determinant of morbidity and mortality.

Karyotypes in affected individuals showed the typical railroad appearance of a centromeric cohesion defect, identifying CAID as a novel cohesinopathy. Although some clinical manifestations overlap between CAID and other cohesinopathies, CAID syndrome is set apart in that it does not cause intellectual and growth retardation. In addition, there are no clinical phenotypes directly associated with the canonical role of SGO1 in centromeric cohesion and sister chromatid segregation, such as premature aging or cancer. Interestingly, fibroblasts from CAID patients showed accelerated cell-cycle progression, a higher rate of senescence, and enhanced activation of transforming growth factor-β (TGF-β) signaling at late passage,[@bib3] identifying clinical cross-talk between the TGF-β and cohesin cascades. Unfortunately, homozygous *Sgo1* knockout mice and homozygous K23E knock-in mice are embryonic lethal (data not shown), leaving only cell-based models for the study of this condition.[@bib9]

The clinical observations raise essential pathophysiological questions about the role of SGO1 and have prompted us to perform unbiased screens to identify the molecular signature of CAID syndrome in vivo along all steps of the central dogma. Here, we investigated how the *SGO1* mutation affects regulation on epigenetic RNA expression and proteomic levels using reduced representative bisulfite sequencing (RRBS), assay for transposase-accessible chromatin with high throughput (ATAC) sequencing, RNA sequencing, and stable isotope labeling with amino acids in cell culture (SILAC) on CAID patient fibroblasts. Because the first symptoms of CAID pathology are not present at birth and appear from 5 years of age onward, the phenotypic manifestations seem to be associated with aging. Thus, the screens were performed on early (passage \[p\]8) and late (p14) passages. We report differential expression of several genes involved in the cohesin complex and cell-cycle regulation, cardiac conduction, and smooth muscle identity and contraction, as well as perturbation of potassium currents in CAID syndrome, canonical TGF-β signaling, DNA methylation, and chromatin compaction. These results expose unanticipated noncanonical roles for SGO1 in CAID pathogenesis and raise important questions for other disorders of gastrointestinal motility.

Results {#sec1}
=======

Transcriptome Profiling of CAID Syndrome {#sec1.1}
----------------------------------------

To characterize the transcriptomic profile of CAID patients homozygous for the SGO1 K23E mutation (MUT/MUT) vs wild-type *SGO1* controls (WT/WT), we performed paired-end RNA sequencing on human dermal fibroblasts from 3 cases and 3 controls at early (p8) and late passages (p14). Consistent with the more pronounced phenotype with aging, we identified 173 down-regulated and 188 up-regulated genes at p8, whereas at p14, we identified 346 down-regulated and 531 up-regulated genes ([Figure 1](#fig1){ref-type="fig"}*A*, [Supplementary Table 1](#appsec1){ref-type="sec"}). Volcano plots of differentially expressed genes at p8 and p14 showed that the vast majority of messenger RNA (mRNA) expression changes observed between CAID patients and controls are less than 4-fold ([Figure 1](#fig1){ref-type="fig"}*B*). Biological functions associated with differentially expressed genes at p8 also were associated with gene expression differences at p14. However, additional biological functions including heart development and contraction, muscle contraction, chromatin compaction, behavior, and potassium channels also were identified at p14 ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, [Supplementary Table 2](#appsec1){ref-type="sec"}). At p8, we identified a specific cluster of up-regulated genes (35 genes) associated with the cell cycle, and this cluster was considerably larger at p14 (109 genes). Of note, we detected up-regulation of the following genes at different levels of significance: *SGO1* itself; *SGO2*, the second member of the shugoshin family involved mainly in meiosis; and Budding Uninhibited By Benzimidazoles 1 (*BUB1*) and *PLK1*, required for SGO1 localization at the centromere ([Figures 1](#fig1){ref-type="fig"}*D* and [2](#fig2){ref-type="fig"}*A*). At early passage (p8), SGO1, SGO2, BUB1, and PLK1 mRNA levels were higher in CAID patients compared with controls, and at late passage (p14) their levels were maintained or up-regulated in CAID patients and decreased in controls. This correlates with overexpression of BUB1 in CAID patients at the protein level ([Figure 3](#fig3){ref-type="fig"}*C* and *D*). Thus, the *SGO1* K23E mutation does not abolish normal SGO1 function in mitosis,[@bib3] but may be associated with causal or compensatory overexpression of SGO1, SGO2, BUB1, and PLK1. Interestingly, we also a noticed a significant up-regulation of *ESCO2*, a gene involved in Roberts syndrome, another cohesinopathy ([Figure 1](#fig1){ref-type="fig"}*D*). This led us to investigate whether other cohesin components are dysregulated as well, and we found a trend toward up-regulation for *AFF4*, *DDX11*, *NIPBL*, *RAD21*, and *SMC3* in CAID patients, although the log~2~ fold changes and/or q values of the mRNA expression levels were below the threshold ([Figure 2](#fig2){ref-type="fig"}*B*). Interestingly, we also found a significant up-regulation of *BIRC5*, an anti-apoptotic gene that binds an amino-terminal motif of SGO1 ([Figure 1](#fig1){ref-type="fig"}*D*).[@bib10] BIRC5 contributes to the control of the total cardiomyocyte number and its cardiac-specific knock-out leads to conduction defects and sino-atrial node dysfunction.[@bib11], [@bib12] We also identified down-regulation of potassium voltage-gated channels *KCNJ2* (Kir2.1), *KCNJ8* (Kir6.1), and *KCND2* (Kv.4.2), suggesting altered potassium channel currents in CAID syndrome ([Figure 1](#fig1){ref-type="fig"}*D*). Taken together, these data suggest that cell-cycle regulation, cardiac conduction, chromatin compaction, and potassium channels are key pathways involved in CAID syndrome.Figure 1**Transcriptomic profiling of CAID patient dermal fibroblasts.** (*A*) Volcano plot of the differentially expressed genes at early (p8) and late stage (p14). Log~2~ fold change: blue, \<-1; red, \>1. (*B*) Number of up-regulated and down-regulated genes identified at early (p8) and late passage (p14). (*C*) Cluster of genes associated with cell cycle identified at p8 that became larger at p14. (*D*) mRNA expression of candidate genes at early (p8) and late passage (p14) showing up-regulation of *SGO1*, *SGO2*, *BUB1*, *PLK1*, *ESCO2*, *DUSP2*, and *BIRC5* and down-regulation of *KCND2*, *KCNJ2*, and *KCNJ8*. Error bars signify SD. For each group, N = 3 independent biological replicates. *P* values were corrected for multiple testing using the Benjamini--Hochberg method (q value). FC, fold change; MUT, K23E; WT, wild-type.Table 1Biological Functions (GO Analysis) Associated With Differentially Expressed Genes in RNA Sequencing at Early Passage (p8)Biological functions*P* valueGenes, nUp-regulated Cell cycle2.46E-1935 Sister chromatid segregation2.47E-1722 Sister chromatid cohesion9.62E-1012 Extracellular matrix organization4.45E-0410 Actomyosin structure organization6.47E-047 Chromatin remodeling at the centromere5.39E-033Down-regulated ABC transporters8.15E-076 Chemical synaptic transmission1.42E-0414 Behavior2.54E-0413 Actin-mediated cell contraction8.25E-034Table 2Biological Functions (GO Analysis) Associated With Differentially Expressed Genes in RNA Sequencing at Late Passage (p14)Biological functions*P* valueGenes, nUp-regulated Cell cycle8.46E-64109 Sister chromatid segregation1.60E-4963 Sister chromatid cohesion7.92E-3037 Chromatin remodeling1.40E-0616 Histones phosphorylation1.69E-057 Cardiac muscle fiber development8.80E-043 Actin filament-based movement3.21E-039 Cardiac muscle hypertrophy in response to stress6.36E-034 Developmental growth9.47E-0323Down-regulated Cardiac conduction1.87E-049 Circulatory system process5.19E-0418 Behavior5.39E-0419 Muscle contraction7.45E-0410 Potassium ion transport2.20E-0310 ABC transporters3.72E-034 Heart contraction5.63E-0310Figure 2**Candidates validation and expression profile of cohesinopathies genes.** (*A*) Reverse transcription quantitative PCR (qPCR) validations of SGO1, SGO2, BUB1, PLK1, DUSP2, and KCND2 expression at early (p8) and late (p14) passage. Error bars signify SD. For each condition, the experiment was performed on N = 3 independent biological replicates in technical replicates. Significance was calculated using 1-way analysis of variance with the Bonferroni post-test (^•^*P* \< .1, \**P* \< .05, and \*\**P* \< .01). (*B*) mRNA expression levels of genes involved in cohesinopathies at early (p8) and late (p14) passage. AFF4, CHOPS syndrome; DDX11, Warsaw breakage syndrome; NIPBL, RAD21, and SMC3, Cornelia de Lange syndrome. Error bars signify SD. *P* values were corrected for multiple testing using the Benjamini--Hochberg method (q value). For each group, N = 3 independent biological replicates. MUT, K23E; WT, wild-type.Figure 3**Proteomic profiling of CAID patient dermal fibroblasts**. (*A*) Venn diagram of proteins differentially expressed in CAID patient/control duos at early (p10) and late passage (p14). (*B*) Protein network of differentially expressed proteins in CAID patients at early (p10) and late (p14) passage. N = 3 independent biological replicates were analyzed for each condition. *P* values were corrected for multiple testing using the Benjamini--Hochberg method (q value). (*C*) Western blot validation of TPM1, TAGLN, and BUB1 overexpression. (*D*) Densitometric quantification of BUB1, TAGLN, and TPM1 overexpression by Western blot. Error bars signify SD. For each group, N = 3 independent biological replicates (2 independent experiments). Significance was calculated by 1-way analysis of variance with the Bonferroni post-test (\**P* \< .05, \*\**P* \< .01). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MUT, K23E; WT, wild-type.

Proteome Profiling of CAID Syndrome {#sec1.2}
-----------------------------------

To investigate the effect of the *SGO1* K23E mutation on protein expression, we performed SILAC on human dermal fibroblasts from 3 CAID patients and 3 controls. Cells were mixed together in a 1:1 ratio to form 3 duos composed of a wild-type control and a CAID patient. Because the global protein expression between duos was highly variable, we decided to look specifically at proteins expressed differentially in more than 1 duo ([Figure 3](#fig3){ref-type="fig"}*A*, [Supplementary Table 3](#appsec1){ref-type="sec"}). At the earliest passage accessible by SILAC (p10), we detected 458 proteins, whereas at late passage (p14), 551 proteins were detected. At early passage (p10), 22 proteins were expressed differentially (q value ≤ 0.01) between duos, whereas at late passage (p14), we identified 20 proteins ([Figure 3](#fig3){ref-type="fig"}*B*). Gene ontology (GO) analysis showed that most of them are involved in extracellular matrix organization, regulation of actin cytoskeleton, and cardiac and smooth muscle contraction ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}, [Supplementary Table 4](#appsec1){ref-type="sec"}). We identified tropomyosin (TPM)1, TPM2, and TPM4, and Transgelin (TAGLN) as interesting biological candidates. TPMs code for tropomyosin family members, which play a major role in cardiac and smooth muscle contraction through CALD1 binding and subsequent actin cytoskeleton stabilization.[@bib13] TAGLN, also known as SM22α, is an actin-binding protein from the calponin family that has been suggested to regulate smooth muscle contractility through regulation of Ca^2+^-independent contractions.[@bib14] Overexpression of TPM1 and TAGLN in CAID patients also has been confirmed at the protein level using Western blot ([Figure 3](#fig3){ref-type="fig"}*C* and *D*). These results designate smooth muscle contraction through TPMs and TAGLN as a plausible pathway involved in the CAID gastrointestinal phenotype.Table 3Biological Functions (GO Analysis) Associated With Differentially Expressed Proteins in SILAC at Early Passage (p8)Biological functions*P* valueGenes, nAssembly of collagen fibrils and other multimeric structures1.85E-095Smooth muscle contraction2.93E-084Supramolecular fiber organization1.94E-088Cardiac muscle contraction4.36E-053Hypertrophic cardiomyopathy5.26E-053Dilated cardiomyopathy6.69E-053Actin-mediated cell contraction1.22E-043Extracellular matrix organization2.00E-044Response to oxidative stress5.11E-044Muscle organ development4.85E-033Table 4Biological Functions (GO Analysis) Associated With Differentially Expressed Proteins in SILAC at Late Passage (p14)Biological functions*P* valueGenes, nSmooth muscle contraction2.93E-084Muscle contraction2.93E-054ECM proteoglycans3.88E-053Cardiac muscle contraction4.36E-053Hypertrophic cardiomyopathy5.26E-053Dilated cardiomyopathy6.69E-053Striated muscle cell differentiation9.15E-054Actin-mediated cell contraction1.22E-043Extracellular matrix organization1.26E-044Adrenergic signaling in cardiomyocytes2.69E-043[^1]

Gastrointestinal Histology of CAID Syndrome {#sec1.3}
-------------------------------------------

To confirm the results of unbiased screens of the CAID proteome and transcriptome, we performed immunohistochemistry by 3,3′-diaminobenzidine tetra hydrochloride (DAB) and fluorescence staining on gut biopsy specimens. We performed staining in the absence of primary antibody (negative control) to make sure that the signal was not caused by nonspecific tissue reactivity ([Figures 4](#fig4){ref-type="fig"}*A* and [5](#fig5){ref-type="fig"}*B*). We further confirmed our results through an immunizing peptide blocking experiment to ensure the specificity of the antibodies used ([Figure 5](#fig5){ref-type="fig"}*A*). These experiments show BUB1 overexpression in the gut of CAID patients ([Figure 4](#fig4){ref-type="fig"}*C*), which is most striking in the muscularis externa and intestinal villi ([Figure 5](#fig5){ref-type="fig"}*C*). Similarly, SGO1 expression is higher in CAID patients compared with controls and this differential expression is enhanced in the muscularis externa and the villi ([Figures 4](#fig4){ref-type="fig"}*B* and [5](#fig5){ref-type="fig"}*C*). Finally, we found TAGLN to be overexpressed specifically in the muscularis mucosa and muscularis externa of CAID patients ([Figures 4](#fig4){ref-type="fig"}*D* and [5](#fig5){ref-type="fig"}*D*). We previously reported thinning of smooth muscle layers, disruption of fiber architecture of smooth muscles, and extensive fibrosis, a hallmark of chronic TGF-β activation, in CAID patient guts.[@bib3] Taking this into consideration, overexpression of TAGLN in muscular layers might be indicative of reparative changes. Such changes could indicate either a causal pathomechanism or compensatory processes in damaged tissues. In summary, these results suggest a possible role of SGO1 and BUB1 in CAID gastrointestinal phenotype.Figure 4**Gastrointestinal histology of CAID patients.** Biopsy specimens (5 μm) from controls and individuals with CAID. All biopsy specimens are oriented to show the villi on top and the muscularis externa at the bottom. (*A*) Negative controls show that no signal was obtained in the absence of the primary antibody. (*B--D*) DAB staining was performed for SGO1, BUB1, and TAGLN. (*B*) SGO1 and (*C*) BUB1 show higher expression in the villi and muscularis externa of CAID patient intestines vs controls. (*D*) TAGLN shows higher expression in muscularis mucosa and muscularis externa in CAID patient intestines vs controls (N = 3, 2 shown). Experiment was performed 3 times independently on 3 biological replicates for each condition. The *Scale bar* is 1000 μm except MUT/MUT1 SGO1, BUB1, TAGLN, and MUT/MUT 2 TAGLN where *Scale bar*: 2000 μm. Images were acquired using a Zeiss AxioScan Z1 slide scanner and processed with Zen software. MUT, K23E; WT, wild-type.Figure 5**Gastrointestinal fluorescent histology of CAID patients**. Biopsy specimens (5 μm) from controls and individuals with CAID. All biopsy specimens are oriented to show the villi on top and the muscularis externa at the bottom. (*A*) Immunizing peptide blocking experiment showing the specificity of BUB1 and TAGLN antibodies. (*B*) Negative controls showing that no signal was obtained in the villi (SGO1 and BUB1), the muscularis mucosa (TAGLN), and the muscularis externa (SGO1, BUB1, and TAGLN) in the absence of the primary antibody. (*C* and *D*) Fluorescence staining was performed for SGO1, BUB1, and TAGLN. (*C*) SGO1 and BUB1 expression were higher in the villi and muscularis externa of CAID patient intestines vs controls. In controls, SGO1 expression was mainly nuclear whereas in CAID patients, SGO1 was delocalized to the cytoplasm. (*D*) TAGLN expression was higher in the muscularis mucosa and the muscularis externa in CAID patient intestines vs controls. V, villi; ME, muscularis externa; MM, muscularis mucosa (N = 3, 2 shown). Experiment was performed 3 times independently on 3 biological replicates for each condition. *Scale bar*: 100 μm. Images were acquired at 40× using a Leica DMi8 inverted fluorescence microscope and processed with Leica LAS X software. DAPI, 4′,6-diamidino-2-phenylindole. MUT, K23E; WT, wild-type.

Electrophysiology of Potassium Channels in CAID Fibroblasts {#sec1.4}
-----------------------------------------------------------

Because we noticed a decrease of KCNJ2, KCNJ8, and KCND2 mRNA levels, we explored potential contributions of different potassium currents to the pathogenesis of CAID syndrome by performing electrophysiology on CAID patient dermal fibroblast cell lines. We identified the inward rectifying potassium current (IK~1~) to be reduced significantly in CAID patient cell lines vs controls ([Figure 6](#fig6){ref-type="fig"}*A* and *B*). The resting membrane potential (RMP), controlled by IK~1~, was decreased accordingly ([Figure 6](#fig6){ref-type="fig"}*C*). However, no difference was detected in the outward potassium current (including the Transient outward potassium current \[I~to~\]) ([Figure 6](#fig6){ref-type="fig"}*D* and *E*). These findings suggest that IK~1~ is impaired in CAID syndrome and could lead to an imbalance in cell excitability.Figure 6**Electrophysiology of CAID patient dermal fibroblasts and analysis response of the canonical and noncanonical TGF-β pathways.** (*A*) I~K1~ recordings (at 0.1 Hz) from controls and CAID patient human dermal fibroblasts. Typical response to Ba^2+^. (*B*) Means ± SEM Ba^2+^-sensitive current density vs voltage relationships in controls (n = 8 cells) vs CAID patients (n = 8 cells). Significance was calculated by 2-way analysis of variance with the Bonferroni post-test (\*\**P* \< .01 and \*\*\**P* \< .001). (*C*) Means ± SEM RMP in controls (n = 8 cells) vs CAID patients (n = 13 cells). Significance was calculated using the Student *t* test with Bonferroni correction. (*D*) Time- and voltage-dependent outward currents in human fibroblasts. Outward currents were elicited by 200-ms voltage steps from a holding potential of −40 mV to membrane potentials between −30 to +60 mV. (*E*) Means ± SEM of current density vs voltage relationships for time-dependent outward currents in human fibroblasts. There were no significant differences between controls (n = 11 cells) and CAID patients (n = 18 cells). Significance was calculated by 2-way analysis of variance with the Bonferroni post-test (\*\**P* \< .01 and \*\*\**P* \< .001). All experiments were replicated 10 times independently with a minimum of 8 cells each time, on N = 1 biological replicate for control, and N = 2 biological replicates for CAID patients. (*F*) Phosphorylation of SMAD3 was increased significantly at baseline and after stimulation with TGF-β1 in CAID patients (N = 3, n = 6) vs controls (N = 3, n = 6) at early (p8) (0--0.1 ng/mL, NS; 0.01--10 ng/mL, *P* \< .001) and late passage (p14) (*P* \< .001). Phosphorylation of p38 and ERK1/2 was increased significantly in controls (N = 3, n = 6) at p14, but not in CAID patients (N = 3, n = 6). At early passage (p8) controls and CAID patients were not sensitive to ligand stimulation. Phosphorylation analysis of JNK1/2/3 showed that controls (N = 3, n = 6) and CAID patients (N = 3, n = 6) were not sensitive to ligand stimulation for both passages studied. Significance was calculated by 2-way analysis of variance with the Bonferroni post-test (\**P* \< .01, and \*\*\**P* \< .001). (*G*) Dose-response analysis of the canonical (SMAD3) and non-canonical (p38) TGF-β pathway. (N = 3, n = 6). Significance was calculated by 2-way analysis of variance with the Bonferroni post-test (∗*P* \< .01, and ∗∗∗*P* \< .001). All experiments were performed 4 times independently. MUT, K23E; WT, wild-type.

Characterization of TGF-β Signaling in CAID Patient Fibroblasts {#sec1.5}
---------------------------------------------------------------

Because TGF-β signaling is clinically relevant in arrhythmias and plays a role in CAID syndrome,[@bib3], [@bib15] we quantified the response to ligand stimulation of canonical and noncanonical TGF-β signaling pathways in CAID patients to further investigate the impact of the *SGO1* K23E mutation. First, we confirmed the known activating effect of the *SGO1* K23E mutation on the canonical pathway by measuring SMAD3 phosphorylation ([Figure 6](#fig6){ref-type="fig"}*F*). Independent of genotype, there was a significant increase of SMAD3 phosphorylation between early (p8) and late (p14) passage. At early passages (p8), there was no biologically meaningful difference in SMAD3 phosphorylation. At late passage (p14), SMAD3 phosphorylation was significantly higher in CAID patients, regardless of the TGF-β1 concentration used, even without stimulation. These results confirmed that SGO1 K23E increases Phospho-SMAD3 (pSMAD3) with and without stimulation and that this effect is enhanced with cell aging. At early passage (p8), the half-maximal effect (median effective concentration) is reached earlier in patients vs controls (0.0120 vs 0.0014 ng/mL), an effect that is lost at p14 (median effective concentration, 0.007 vs 0.010 ng/mL) ([Figure 6](#fig6){ref-type="fig"}*G*). This suggests that although pSMAD3 increases, the sensitivity to the TGF-β1 ligand is higher only at early passages. We analyzed the response of the noncanonical TGF-β pathway by means of Phosphop38 mitogen-activated protein kinase (MAPK), Phospho-extracellular signal--regulated kinase (ERK)1/2, and p-c-Jun-N-terminal kinase (JNK)1/2/3 measurements. This analysis showed that only wild-type fibroblasts, but not CAID cell lines, acquired a sensitivity to ligand stimulation at passage 14, but not at early passages for pp38 MAPK and pERK1/2 ([Figure 6](#fig6){ref-type="fig"}*F* and *G*). Interestingly, stimulation with TGF-β1 had no effect on the phosphorylation of JNK1/2/3 for both genotypes ([Figure 6](#fig6){ref-type="fig"}*F*). These results show a surprising uncoupling of the 2 pathways, potentially through a specific interaction with BUB1. In addition, at passage 14, we identified up-regulation of DUSP2, a dual-specificity phosphatase known to dephosphorylate ERK1/2, p38, and JNK ([Figure 1](#fig1){ref-type="fig"}*D*).[@bib16] Cumulatively, these analyses point to an up-regulation of canonical TGF-β signaling and uncoupling of canonical from noncanonical signaling in CAID pathology.

Epigenomics of CAID Syndrome {#sec1.6}
----------------------------

RNA sequencing analysis identified several differentially expressed genes as well as chromatin-related pathways in CAID patients, prompting us to study a potential role of SGO1 in epigenetic regulation through DNA methylation and chromatin compaction. To survey the methylation profile of CAID patients vs controls genome-wide at early (p8) and late (p14) passage, we used RRBS. A total of 375,002 tiles and 497,974 tiles, respectively, were interrogated at early (p8) and late passage (p14); *tile* refers to a 100-bp region containing a minimum of 2 CpG islands. A total of 4702 (4498 hypermethylated, 204 hypomethylated) and 2746 (2568 hypermethylated, 178 hypomethylated) differentially methylated tiles (≥30% methylation difference) were detected at early (p8) and late passage (p14), respectively ([Figure 7](#fig7){ref-type="fig"}*A--C*, [Supplementary Table 5](#appsec1){ref-type="sec"}). Surprisingly, we found that CAID patients have significantly higher global methylation than controls for both passages. A total of 95.7% and 93.5% of the altered regions are hypermethylated in CAID patients at early (p8) and late passage (p14), respectively, pointing to global DNA hypermethylation as a possible pathomechanism in CAID syndrome. Differentially methylated tiles in genic regions (introns, exons, promoter--transcription starting site, termination -transcription termination site, 3' untranslated region, and 5' untranslated region) were associated with several biological pathways including heart and smooth muscle contraction, cellular potassium ion transport, as well as neuronal system process and behavior, features that are found commonly in other cohesinopathies ([Tables 5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"}, [Supplementary Table 6](#appsec1){ref-type="sec"}). Of note, we identified regions associated with cellular potassium ion transport genes, supporting the hypothesis of a deregulation of potassium channels in CAID. However, no hypermethylation was observed in *KCND2*, *KCNJ2*, and *KCNJ8* genic regions. The global hypermethylation pattern also was confirmed by pyrosequencing of 2 CpG sites in Long interspersed nuclear element (*LINE-1*) retrotransposons, which cover approximately 17% of the genome.[@bib17] We observed significantly higher *LINE-1* methylation genome-wide in CAID patients for both passages studied ([Figure 7](#fig7){ref-type="fig"}*D*). At early passage (p8), we observed an increase in methylation percentage of approximately 15% and 5% for the CpG1 and the CpG2 sites, respectively. Similar results were obtained at late passage (p14), where an increase in methylation percentage of approximately 10% and 5% was observed for the CpG1 and the CpG2 sites, respectively.Figure 7**Epigenetic profile of CAID patients.** (*A*) Heatmap representation of methylation levels in CAID patients vs controls among all tiles at early (p8) and late stage (p14) showed a global hypermethylation pattern. (*B*) Volcano plot of the methylation difference (%) at early (p8) and late stage (p14). Yellow ≥-30% and blue ≥30% methylation differences. (*C*) Tile proportions of differentially methylated regions at early (p8) and late stage (p14). For each group, N = 3 independent biological replicates. *P* values were corrected for multiple testing using the Benjamini--Hochberg method (q value). (*D*) Methylation percentage of *LINE-1* CpG sites assessed by pyrosequencing. *LINE-1* CpGs are significantly more methylated in CAID patients than in controls. Error bars signify SD. For each condition, the experiment was performed on N = 3 independent biological replicates in technical replicates. Significance was calculated by 1-way analysis of variance with the Bonferroni post-test (^•^*P* \< .1, \**P* \< .05, and \*\*\**P* \< .001). (*E*) Heatmap representation of chromatin compaction level in CAID patients vs controls among all tiles at early (p8) and late stage (p14). (*F*) Volcano plot of the log~2~ fold change of Transposase differential peaks at early (p8) and late stage (p14). Blue, log~2~ fold change \<-1; red, log~2~ fold change \>1. (*G*) Proportion of Transposase differential peaks at early (p8) and late stage (p14). For each group, N = 3 independent biological replicates. *P* values were corrected for multiple testing using the Benjamini--Hochberg method (q value). MUT, K23E; TSS, transcription starting site; TTS, transcription termination site; UTR, untranslated region; WT, wild-type.Table 5Biological Functions (GO Analysis) Associated With Differentially Methylated Genes in RRBS at Early Passage (p8)Biological functions*P* valueGenes, nHypermethylated Neuronal system7.21E-1473 Regulation of membrane potential1.04E-0660 Behavior1.24E-0677 Regulation of heart contraction6.91E-0537 Muscle contraction9.72E-0548 Cellular potassium ion transport1.76E-0431 Midgut development8.59E-045 Neuromuscular process2.58E-0321 Smooth muscle contraction3.42E-033Hypomethylated Embryonic morphogenesis7.81E-0615 Heart morphogenesis3.24E-059 Cardiovascular system development1.41E-0415 Heart looping6.29E-044 Embryonic heart tube development1.63E-033 Regulation of developmental growth4.80E-037 Negative regulation of MAPK cascade5.78E-035 Actin filament-based process6.78E-0311Table 6Biological Functions (GO Analysis) Associated With Differentially Methylated Genes in RRBS at Late Passage (p14)Biological functions*P* valueGenes, nHypermethylated Neuronal system4.82E-0639 Cardiac conduction2.49E-0520 Muscle contraction6.85E-0524 Behavior3.19E-0447 Regulation of membrane potential4.19E-0436 Cellular potassium ion transport8.25E-0421 Midgut development1.39E-034 Actin filament-based process1.39E-0350 Hindgut development5.34E-033Hypomethylated Embryonic morphogenesis4.52E-0412 Regulation of embryonic development1.33E-035 Regulation of cellular response to stress1.38E-0312 Chromatin organization2.23E-037 Negative regulation of response to wounding2.24E-034 Heart morphogenesis4.98E-036 Pathway-restricted SMAD phosphorylation2.47E-033 Muscle structure development9.26E-0310[^2]

The striking global methylation signature of CAID prompted us to perform ATAC sequencing on 3 controls and 3 CAID patient cell lines at early (p8) and late passage (p14) to assess the chromatin accessibility profile (Transposase peaks). In parallel with these findings, we observed a mild chromatin closing signature at early (p8) passage, which was enhanced at late (p14) passage, suggesting that at late passage (p14) the effect of the mutation was stronger ([Figure 7](#fig7){ref-type="fig"}*E--G*, [Supplementary Table 7](#appsec1){ref-type="sec"}). Transposase peaks near the gene transcription starting site were associated mainly within the same pathways identified by RNA sequencing and RRBS analysis ([Tables 7](#tbl7){ref-type="table"} and [8](#tbl8){ref-type="table"}, [Supplementary Table 8](#appsec1){ref-type="sec"}). In aggregate, these data suggest that epigenetic modifications at methylation and chromatin configuration levels participate in CAID pathogenesis.Table 7Biological Functions (GO Analysis) Associated With Transposase Peaks in ATAC Sequencing at Early Passage (p8)Biological functions*P* valueGenes, nLess open Inwardly rectifying K+ channels5.80E-043 Neuronal system3.49E-037 Actin filament-based process3.88E-0310 Action potential6.38E-034 Potassium ion transport8.71E-035More open Regulation of nervous system development5.31E-0513 Apoptotic process involved in development5.30E-043 Developmental growth1.85E-039 Negative regulation of intracellular signal transduction3.20E-038 Limb development8.81E-034Table 8Biological Functions (GO Analysis) Associated With Transposase Peaks in ATAC Sequencing at Late Passage (p14)Biological functions*P* valueGenes, nLess open Protein kinase A signaling1.45E-044 Actin filament-based process1.31E-0314 Heart development3.53E-0311 Cellular potassium ion transport5.36E-036 Neuronal system9.25E-038More open Vasculogenesis5.64E-066 Cardiovascular system development9.39E-0412 Developmental growth8.39E-039 Muscle tissue development8.55E-037 Cardiac muscle tissue development9.31E-035

Discussion {#sec2}
==========

CAID syndrome is part of the cohesinopathy family, alongside Cornelia de Lange syndrome (*NIPBL*, *RAD21*, *SMC1A*, *SMC3*, and *HDAC8*), Robert syndrome (*ESCO2*), Warsaw breakage syndrome (*DDX11*), and others that result from mutations in cohesin complex components. Although there is some phenotypic overlap between CAID and other cohesinopathies (valve defects and gastrointestinal defects), CAID patients do not show intellectual or growth retardation. In addition, the clinical manifestations observed in CAID syndrome are difficult to reconcile with perturbation of canonical roles of SGO1 in cell cycling, suggesting that novel noncanonical roles of SGO1 are involved in CAID pathology. It has been shown over recent years that components of the cohesin complex play important roles in long-range transcriptional regulation.[@bib18], [@bib19] Indeed, RAD21, SMC1A, and other interaction partners of SGO1 are involved in transcription regulation.[@bib20], [@bib21] Thus, a noncanonical role of SGO1, possibly through 11-Zinc Finger Protein (CTCF) loading, chromatin remodeling, and epigenetic marks, in maintaining transcriptional modules during cardiac and intestinal development therefore is likely.[@bib21], [@bib22] The early embryonic lethality of most cohesin component knockouts makes it impossible to precisely replicate cohesinopathies in mice without use of more sophisticated models. Homozygous *Sgo1* knockout mice and homozygous K23E knock-in mice are embryonic lethal, leaving dermal fibroblasts and intestinal biopsy specimens from CAID patients as the only proxy available for characterization and understanding of the mechanisms involved in CAID syndrome[@bib9] (and data not shown).

In this study, we therefore follow all steps of the transcriptional cascade from epigenetics to proteomics to define a molecular signature of CAID syndrome. Although we did not identify a single driver pathway in CAID pathogenesis, multiple cumulative hits within related cascades seem to converge on a transcriptional dysregulation influenced by epigenetic and TGF-β--related events. At the mRNA level, especially at late passage (p14), the most striking finding is up-regulation of *SGO1* and *SGO2*, along with many other genes involved in cell cycling or the cohesin complex, including direct interactors such as *BUB1*, *PLK1*, and *BIRC5*. Given that CAID fibroblasts show centromeric cohesion defects with only mild acceleration of cell cycling and without any impact on fidelity of mitosis or integrity of the genome,[@bib3] the observed effects of the *SGO1* K23E mutation may be mainly compensatory. In fact, it is conceivable that overexpression of SGO1, SGO2, BUB1, and PLK1 can attenuate the direct effects of *SGO1* K23E. Future studies should be directed at dissecting whether this overexpression is compensatory or causal.

In addition, recent publications have described noncanonical postmitotic cohesin functions. The serine/threonine kinase BUB1, previously recognized to play an important role in establishing the mitotic spindle checkpoint, now has been found to be required for canonical and noncanonical TGF-β signaling through type Transforming Growth Factor Beta Receptor 1 (TGFBRI) recruitment.[@bib23] This raises the possibility that enhanced TGF-β signaling in CAID patient cell lines is the result of overexpression of BUB1. Furthermore, we show here that *SGO1* K23E uncouples canonical and noncanonical TGF-β signaling: while canonical TGF-β signaling is enhanced in CAID patient fibroblasts at early passage and increases further with late passage, a concomitant increase of noncanonical signaling occurs only in wild-type fibroblasts, but not CAID cell lines. This surprising uncoupling of the 2 TGF-β signaling pathways suggests that the *SGO1* K23E mutation favors the canonical pathway through an unknown mechanism, possibly through a specific interaction with BUB1. This hypothesis is strengthened by the overexpression and the similar localization pattern of SGO1 and BUB1 in the villi and the muscularis externa from CAID patient intestines. On the other hand, the up-regulation of *DUSP2* correlates with the inhibition of the noncanonical ERK1/2 MAPK, p38, and JNK signaling in CAID. All these results point to canonical TGF-β signaling as a key cascade involved in the intestinal manifestations of CAID syndrome and is a clinical identification of cross-talk between the TGF-β and cohesin cascades.

Interestingly, we also identified a trend toward up-regulation for genes involved in other cohesinopathies, with the most drastic changes for *ESCO2*, *RAD21*, and *SMC3*. Autosomal-dominant mutations in *RAD21* and *SMC3* have been associated with Cornelia de Lange syndrome, whereas recessive mutation in *RAD21* has been found in CIPO. An analysis of *RAD21* mutations and depletion in zebrafish models showed impaired cellular DNA damage response, disrupted transcription and intestinal transit, and the development of enteric neurons, similar to patients with CIPO, suggesting that these manifestations result from a loss-of-function of RAD21, while in our case, we found an up-regulation of *RAD21*, potentially representing a causal or compensatory mechanism.[@bib8], [@bib24] In most cases, *SMC3* and *ESCO2* mutations do not cause gastrointestinal defects.

Even with recent advances in the proteomic field, characterization of the CAID patient proteome was challenging. Because the dynamic range of SILAC for protein identification and quantification in human beings can vary between 1000 and 5000, the whole proteome is not covered.[@bib25] The workflow of SILAC performs a single comparison between a control and a CAID patient without a cross-link between the different samples, giving rise to a lot of variations between duos. Furthermore, SILAC cannot detect proteins expressed at low levels, as was the case of several candidate genes identified by RNA sequencing. However, investigation of the proteome in CAID syndrome showed valuable insight into CAID pathomechanisms. We identified TPM1 and TAGLN as important genes overexpressed in CAID syndrome. Because TPM1 and CALD1 regulate smooth muscle contractions through Ca^2+^-dependent actin stabilization, it is conceivable that overexpression of TPM1 perturbs smooth muscle contractions, either through contraction stalling or insufficient compensation (myogenic CIPO).[@bib13] TGF-β signaling positively regulates both TPM1 and TPM2, and increases smooth muscle contractile force and tissue remodeling.[@bib26] TAGLN is a canonical TGF-β--inducible gene acting as an actin--cross-linking/gelling protein of the calponin family, which can regulate actin contractile function through Ca^2+^-independent contraction.[@bib14] Studies on TAGLN-deficient mice showed that TAGLN knock-out significantly inhibited Ca^2+^ independent but not Ca^2+^ dependant vascular contractility.[@bib27] Thus, overexpression of TAGLN might be a causal or compensatory process, either to balance Ca^2+^-dependent and -independent smooth muscle contractions or to bypass the perturbation of contractions secondary to the disruption and fibrosis of smooth muscle observed in CAID patients.

We found that IK~1~ was reduced significantly in CAID patient cell lines vs controls. This observation directly correlated with the down-regulation of *KCNJ2*, the ion-channel subunit that carries IK~1~. The RMP was decreased accordingly. IK~1~ is critically important to establish the resting membrane potential and thereby control excitability of a wide range of cells.[@bib28] The large changes in IK~1~ that we observed in CAID patient cells were strong candidates to underlie abnormalities in fibroblast, cardiomyocyte, and colonic functions.[@bib29], [@bib30], [@bib31] Further work is needed to relate this ion-channel dysfunction to specific components of CAID pathophysiology.

The results of this study also support the idea that CAID syndrome is a transcriptional dysregulation disorder. In addition to the unique differentially expressed gene network identified by RNA sequencing, the global methylation pattern observed in patients as well as the chromatin compaction signature suggest that epigenetic regulation has pathogenetic significance in CAID syndrome. This assertion was strengthened further by the significantly higher methylation of *LINE-1* retrotransposons in CAID patients. Indeed, pyrosequencing of *LINE-1* retrotransposons, representing approximately 17% of the human genome, is a well-established technique to survey global DNA methylation.[@bib17] Although DNA methylation is commonly associated with gene silencing, such a correlation was not found in our study. This is in line with recent studies showing that methylation can maintain gene expression through promoter blocking, and that gene down-regulation results from DNA methylation-independent mechanisms.[@bib32], [@bib33] As an example, increased DNA methylation in the gene body can result in increased gene expression.[@bib34], [@bib35] Although RRBS provides a large (∼1.5 million CpG) but partial view of the 30 million CpGs present in the genome, only a portion of indicative regions regulating gene expression (ie, promoters and enhancers) were evaluated. Nevertheless, RNA sequencing, RRBS, and ATAC sequencing analysis converged on common pathways in CAID and underscored a noncanonical role of SGO1 in transcriptional regulation through chromatin remodeling and epigenetic marks.

In conclusion, intestinal manifestations of CAID syndrome most likely result from several changes with a cumulative effect, and not a single dysregulated gene. We point out the dysregulation of canonical TGF-β signaling, DNA hypermethylation, chromatin compaction, and a decrease of IK~1~ as a vicious cycle producing the striking intestinal manifestations of CAID syndrome. Dysregulation of druggable pathways such as the TGF-β cascade and methylation may provide targets toward the identification of medical therapies for CAID syndrome, but also for study in other gastrointestinal conditions such as CIPO and irritable bowel syndrome, which affect patients worldwide.

Materials and Methods {#sec3}
=====================

All authors had access to the study data and reviewed and approved the final manuscript.

Skin Biopsy Specimens and Cell Lines {#sec3.1}
------------------------------------

Human tissue acquisition from CAID patients was approved by the ethical committees at all participating institutions. Primary human dermal fibroblasts were derived from skin biopsy specimens from 3 wild-type controls and 3 CAID patients. The study was conducted after patients provided informed consent. All assays were performed at early (p8--p10) and a late (p14) passage. Primary dermal fibroblast; normal, human, adult (ATCC PCS201012, lots 61447289 and 61683453) and BJ (ATCC CRL-2522) have been used as control cell lines for SILAC experiments. All cell lines routinely were tested for the absence of mycoplasma infection.

Transcriptomic Studies {#sec3.2}
----------------------

### RNA extraction, library preparation, and RNA sequencing {#sec3.2.1}

RNA extraction from human dermal fibroblasts (3 controls and 3 CAID patients) at p8 and p14 was performed using the miRNAeasy mini kit (217004; Qiagen, Hilden, Germany) on an automated QIAcube (Qiagen) according to the manufacturer's instructions. The complementary DNA libraries were generated on 500 ng of RNA with RNA integrity number greater than 9 using the Illumina TruSeq Stranded Total RNA Sample preparation kit (20020596; Illumina, San Diego, CA). Libraries were sequenced over multiple flow cells on the paired-end, 100-bp Illumina Hiseq4000.

### RNA sequencing data processing and analysis {#sec3.2.2}

Trimmomatic (v.0.32; Usadel lab, Jülich and Aachen, Germany) was used to remove Illumina adapters from the raw reads.[@bib36] Reads with a quality score less than 30 and smaller than 32 bp were eliminated. The remaining reads were mapped to the human genome 19 (hg19) reference using Bowtie2 (v.2.1.0; Johns Hopkins University, Baltimore, MD) and TopHat (v.2.1.0; Johns Hopkins University).[@bib37], [@bib38] FeatureCounts (v.1.4.4 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia) was used to count mapped reads.[@bib39] The weighted trimmed mean of M values algorithm in the edgeR package (Bioconductor; Roswell Park Comprehensive Cancer Center, Buffalo, NY) was used to normalize gene expression levels across samples.[@bib40] The data were log-transformed, and we applied voom function in the limma package (Bioconductor) to get precision-weights data.[@bib41] Limma also was used to perform a weighted fit on the weighted data obtained from voom using the lmFit function. To investigate genotype effects on gene expression in dermal fibroblasts at passages 8 and 14, we used a nested linear model with the following design: gene expression ∼ sex + biopsy_age + genotype:passage. Nominal *P* values provided by lmFit were corrected for multiple testing using the Benjamini--Hochberg method. Sex chromosomal or low-count genes with an average read count less than 10 across all samples were excluded, resulting in 13,920 genes in total. Genes with a log~2~ fold change greater than 1 and less than -1 were considered as up-regulated and down-regulated, respectively. False discovery rate (FDR)-adjusted *P* value (q value) less than .1 was considered significant. The complete list of differentially expressed genes can be found in [Supplementary Table 1](#appsec1){ref-type="sec"}. GO analysis was performed using Metascape (<http://metascape.org>).[@bib42] The complete GO analysis results can be found in [Supplementary Table 2](#appsec1){ref-type="sec"}.

### Real-time polymerase chain reaction validations {#sec3.2.3}

RNA was reverse-transcribed into complementary DNA using SuperScript IV Reverse Transcriptase (18090050; Invitrogen, Carlsbad, CA). Real-time polymerase chain reaction (PCR) was performed with FastStart Universal SYBR Green Master (11340500; Roche, Bâle, Suisse) using a LightCycler 96 Real-Time PCR system (Roche). Transcripts were normalized to *GAPDH* ([Table 9](#tbl9){ref-type="table"}).Table 9Primers List for Reverse-Transcription PCR ValidationsGene IDForward 5\' primer sequenceReverse 3\' primer sequence*BUB1*TCAGCCTGGTTTTGAATTCCTCTACCACAATGACCCAAGATTCA*DUSP2*GTAGCGGAAAAGGCCCTCAAGTCCCGATCTGTGCTCTGAG*KCND2*CTGGGGTACACACTGAAGAGTTACTCAGCGAACAGATAGAACCA*PLK1*CCAACCATTAACGAGCTGCTTAACCTGTCTCTCGAACCACTG*SGO1*CTGGAGCTGTCATCACTATTGGCCAAAGTGAAAGAAGCCCAAGA*SGO2*GAGTGCCCAGTGATGGAAACAATGCCCTGTTGTTGTGCTTTA

Proteomic Studies {#sec3.3}
-----------------

### Cell culture and SILAC {#sec3.3.1}

SILAC Dulbecco\'s modified Eagle medium without L-arginine and L-lysine (88364; Thermo Fisher Scientific, Waltham, MA) was supplemented with 13C6, 15N4 L-arginine (20104102; Silantes, München, Germany), 13C6, and 15N2 L-lysine (2111604102; Silantes), or unlabeled 12C614N4 L-arginine (A5006; Sigma Aldrich, St. Louis, MO) and 12C6L-lysine (L5501; Sigma Aldrich) to produce heavy and light SILAC media, respectively. L-proline (P5607; Sigma Aldrich) also was added to a final concentration of 100 μg/mL to prevent amino acid conversion. A total of 500,000 fibroblasts from 3 controls and 3 CAID patients were seeded and grown in heavy and light medium, respectively, for at least 7 doubling times to ensure complete amino acid incorporation.

### SILAC cell lysis and digestion {#sec3.3.2}

The heavy and light labeled cells were mixed together in a 1:1 ratio to form 3 duos composed of a wild-type control and a CAID patient. The mixed cells were centrifuged at 14,000 rpm at 4°C for 15 minutes. The cell pellets were resuspended in cold lysis buffer (1% sodium deoxycholate \[SDC\] in 50 mmol/L NH4HCO3) and sonicated with the Fisher Scientific Sonic Dismembrator Model 100 to lyse the cells. The samples then were transferred immediately to an Eppendorf Thermomixer R (Eppendorf, Hambourg, Allemagne) and incubated at 99°C for 5 minutes with shaking at 1400 rpm. The samples then were centrifuged at 40,000*g* for 10 minutes at 4°C. The supernatant was harvested, dithiothreitol was added to obtain a (T9284, Sigma Aldrich) final concentration of 5 mmol/L, and the samples were shaken at 800 rpm for 30 minutes at 56°C. After being returned to room temperature, the iodoacetamide was added to a final concentration of 15 mmol/L and the samples were incubated for 30 minutes in the dark. Trypsin was finally added at a final concentration of 5--10 ng/μL with a protein:trypsin ratio of approximately 50:1 to 200:1, and the samples were incubated at 37°C overnight. The enzymatic digestion was stopped by adding 30% Trifluoroacetic acid (TFA) to obtain a final pH of approximately 2 and centrifuged at 13,000*g* for 5 minutes. Peptide digestion (supernatant) was transferred to a new tube and the pellet was washed with 0.1% TFA and then centrifuged again. The supernatant was added to the peptide digestion.[@bib43]

### SILAC desalting, concentration, and mass spectrometry data acquisition {#sec3.3.3}

Samples were loaded on a homemade C18 precolumn directly connected to the switching valve of a homemade reversed-phase column with a gradient from 10% to 60% acetonitrile (0.2% formic acid \[FA\]) and a 600 nL/min flow rate on a NanoLC-2D system (Eksigent, Dublin, CA) connected to an Q-Exactive Plus (Thermo Fisher Scientific). Each full mass spectrometry spectrum acquired with a 70,000 resolution was followed by 12 MS/MS spectra, in which the 12 most abundant multiply charged ions were selected for MS/MS sequencing.

### SILAC data processing and analysis {#sec3.3.4}

Data processing was performed using Maxquant (v1.5.0.25; Max Planck Institue of Biochemistry, Planegg, Germany).[@bib44] Tolerances on precursors and fragments were 15 ppm and 0.01 daltons, respectively. Variable selected post-translational modifications were carbamidomethyl (C), oxidation (M), and deamidation (NQ). SILAC labels selected were R10 (13C6, 15N4) + K8 (13C6, 15N2) for the heavy label. Genes with a fold change greater than 1.5 and less than 0.66 were considered as overexpressed and underexpressed, respectively. FDR-adjusted *P* value (q value) ≤ .01 was considered significant. The complete list of differentially expressed proteins can be found in [Supplementary Table 3](#appsec1){ref-type="sec"}. GO analysis was performed using Metascape (<http://metascape.org>).[@bib42] The complete GO analysis results can be found in [Supplementary Table 4](#appsec1){ref-type="sec"}.

### Western blot validations {#sec3.3.5}

Protein lysates were extracted from fibroblasts. A total of 25 μg of proteins were loaded on 12% sodium dodecyl sulfate--polyacrylamide gel electrophoresis (4561034; Bio-Rad, Hercules, CA) and transferred to a nitrocellulose membrane. Membranes were probed against SGO1 (mouse monoclonal, ab58023; Abcam, Cambridge, UK), BUB1 (mouse monoclonal, sc-365685; Santa Cruz, Dallas, TX), SM22α (rabbit polyclonal, sc-50446; Santa Cruz), and TPM1 (rabbit polyclonal, sc-28543; Santa Cruz) primary antibodies diluted 1:200 followed by horseradish-peroxidase--conjugated secondary antibodies. The blots were developed using SuperSignal (34580; Thermo Scientific). Signal intensity was quantified using ImageJ software (v.1.48; National Institutes of Health, Bethesda, MD).[@bib45]

Tissue Studies {#sec3.4}
--------------

### Immunohistology on intestine {#sec3.4.1}

Paraffin-embedded sections (5-μm thick) were immunostained using the Ultravision LP Detection system horseradish-peroxidase polymer and DAB Plus Chromogen kit (TL-015-HD; Thermo Scientific) for DAB staining. The slides were rehydrated by successive baths (xylene, EtOH 100%, EtOH 90%, EtOH 70%, EtOH 50%, dH~2~O). Antigen retrieval was performed by heating at 68°C for 20 minutes in 1 mmol/L citrate (pH 6.0) and cooled down to room temperature. Slides then were incubated in 0.3% Triton (T9284, Sigma Aldrich) for 30 minutes and blocked in phosphate-buffered saline + 10% serum (goat serum for DAB staining and donkey serum for fluorescent staining). For immunostaining SGO1 (anti-mouse, ab58023; Abcam), BUB1 (mouse monoclonal, sc-365685; Santa Cruz, and rabbit polyclonal, Ab70372; Abcam) and TAGLN (rabbit polyclonal, sc-50446; Santa Cruz) were diluted 1:500 for DAB and 1:200 for fluorescence staining. The primary antibodies were targeted with IgG secondary antibody conjugated to horseradish peroxidase for DAB staining and donkey anti-mouse and anti-rabbit Alexa 555 and 647 for fluorescent staining (1:500 dilution; Molecular Probes/Invitrogen, Carlsbad, CA). DAB immunostainings were counterstained using methyl green and mounted with Permount medium (Thermo Fisher Scientific). Fluorescent immunostainings were mounted with 4′,6-diamidino-2-phenylindole incorporated anti-fade medium (P36962; Thermo Fisher Scientific). Immunohistochemistry control experiments were performed by excluding the primary antibody. Immunizing peptide blocking also was performed following the protocol described earlier. Five times excess of BUB1 (H00000699-Q01; Novus Biologicals, Littleton, CO), and TAGLN (NBP1-45267; Novus Biologicals) human recombinant peptides was added to the primary antibody by weight. Pixel intensity was corrected for noise by subtraction of the immunofluorescence background in negative controls. Imaging of DAB-stained tissues was performed using a Zeiss AxioScan Z1 slide scanner and analyzed with Zen software (Zeiss, Oberkochen, Germany). Fluorescent-stained tissues were imaged using a Leica DMi8 inverted fluorescence microscope (Leica, Wetzlar, Germany) with a 40× objective. Image processing was performed with Leica LAS X software.

Cell Culture Assays {#sec3.5}
-------------------

### Patch clamp: ionic current and RMP recording {#sec3.5.1}

All in vitro recordings were obtained at 37°C. The whole-cell perforated-patch technique was used to record RMP in current-clamp mode, and the tight-seal patch clamp was used to record IK~1~ in voltage clamp mode. Borosilicate glass electrodes filled with pipette solution were connected to a patch-clamp amplifier (Axopatch 200A; Axon Union City, California, USA). Electrodes had tip resistances of 6--8 MΩ. Nystatin-free intracellular solution was placed in the tip of the pipette by capillary action (≈30 s), and then pipettes were backfilled with nystatin-containing (600 μg/mL) pipette solution. IK~1~ was recorded as the 300-μmol/L Ba^2+^-sensitive current. Tyrode solution contained 136 mmol/L NaCl, 1.8 mmol/L CaCl~2~, 5.4 mmol/L KCl, 1 mmol/L MgCl~2~, 0.33 mmol/L NaH~2~PO~4~, 10 mmol/L dextrose, and 5 mmol/L HEPES, titrated to pH 7.3 with NaOH. The pipette solution for RMP, outward potassium current, and IK~1~ recording contained 0.1 mmol/L guanosine triphosphate, 110 mmol/L potassium aspartate, 20 mmol/L KCl, 1 mmol/L MgCl~2~, 5 mmol/L Magnesium ATP (mgATP), 10 mmol/L HEPES, 5 mmol/L sodium phosphocreatine, and 0.005 mmol/L EGTA (pH 7.4, KOH). A total of 10 mmol/L tetraethylammonium was used to block outward potassium current. Junction potentials between bath and pipette solutions averaged 10.5 mV and were corrected for RMP measurements only. Currents are expressed as densities (picoamperes per picofarad (pA/pF)) to control for differences in cell size/capacitance.

### α-Screen TGF-β signaling assays {#sec3.5.2}

The phosphorylation state of SMAD3, p38, ERK1/2, and JNK1/2/3 was quantified using Amplified Luminescence Proximity Homogenous Assays (Perkin Elmer Waltham, Massachusetts, USA). A total of 12,000--15,000 cells/well were seeded in a 24-well plate. Forty-eight hours after plating, the cells were starved overnight in total absence of fetal bovine serum. They then were stimulated with different concentrations of TGF-β1 (0--100 ng/mL) for 1 hour, washed with phosphate-buffered saline, and lysed for 20 minutes at room temperature using 200 μL/well of AlphaScreen SureFire Ultra lysis buffer supplemented with protease inhibitors. The quantifications were performed in 384-well plates (Proxiplate; Perkin Elmer), according to protocol guidelines and measured with the EnVision 2104 plate reader (Perkin Elmer). For each condition, Six independent measurements were performed for each cell line and experiments were repeated four times.

Epigenetic Studies {#sec3.6}
------------------

### Library preparation and RRBS {#sec3.6.1}

DNA extraction from human dermal fibroblasts (3 controls and 3 CAID patients) at p8 and p14 was performed using the QIAamp DNA Mini Kit (51304; Qiagen). A total of 500 ng of genomic DNA was digested with Msp1 overnight at 37°C in an Eppendorf Thermocycler. Without deactivating MspI and cleaning up the digestion reactions, DNA end repair and A-tailing was conducted by adding Klenow fragment (3\'→5\' exo-) (M0212M; New England Biolabs Ipswich, Massachusetts, USA) and dNTP mixture (10 mmol/L deoxyadenosine triphosphate (dATP), 1 mmol/L Deoxycytidine triphosphate (dCTP), and 1 mmol/L Deoxyguanosine triphosphate (dGTP)) directly into each sample in the strip tube. The reaction was incubated at 30°C for 20 minutes and then at 37°C for 20 minutes. Bead clean-up was conducted using AMPure XP beads (B37419AB; Beckman Coulter Brea, California, USA) to remove small fragments. Ligation of NEB methylated adaptors (E7535; New England Biolabs) to DNA samples was performed using the T4 DNA ligase enzyme (M0202S; New England Biolabs) at 20°C for 20 minutes. The USER enzyme (M5505S; New England Biolabs) was added, and the reaction was incubated at 37°C for 15 minutes. The reaction was cleaned up using AMPure XP beads (B37419AB; Beckman Coulter). Bisulfite conversion and clean up then was performed on purified DNA using the EpiTect Fast bisulfite conversion kit (59824; Qiagen). Libraries of the bisulfite-converted DNA were generated by PCR reaction using the PfuTurbo Cx Hotstart DNA Polymerase (600410; Agilent Santa Clara, California, USA), deoxynucleotide triphosphates (dNTPs) (10 mmol/L), NEB indexing primers and NEB universal primers (E7535L; New England Biolabs), coupled with SYBR Green (S7563; Thermo Fisher Scientific). The libraries were cleaned using AMPure XP beads (B37419AB; Beckman Coulter). Paired-end sequencing of the libraries was performed on a paired-end, 125 pb Illumina Hiseq 2500.

### RRBS data processing and analysis {#sec3.6.2}

Bsmap (v.2.6 Dan L Duncan Cancer Center, Houston, Texas, USA) was used for initial data processing, methylation calls, and reads alignment.[@bib46] Analysis and statistics of differentially methylated regions was performed using MethylKit (v.0.5.3 Bioconductor), a software based on the Benjamini--Hochberg FDR procedure (*P* value threshold of q = 0.01).[@bib47] Specific parameters were chosen including 100-bp, step-wise tiling windows, 2 CpG minimum per tile, and a minimum 30× CpG coverage of each tile per sample. The methylation level of a 100-bp tile was the average of all single CpGs within the tile, and the methylation level reported for a sample was the average methylation level across replicates. To identify differentially methylated CpG tiles in CAID patients vs controls at each passage, we used the R package DSS (Bioconductor)[@bib48] with the following model: methylation ∼ sex + biopsy_age + genotype:passage. We defined differentially methylated tiles as those showing a significant difference of methylation at an FDR (q value) \< 0.01, and an absolute mean methylation difference greater than 30% (375,003 and 497,975 tiles in p8 and p14, respectively). HOMER (v.3.51 Salk Institute for Biological Studies, La Jolla, California, USA) was used to annotate differentially methylated sequences.[@bib49] The complete list of differentially methylated regions can be found in [Supplementary Table 5](#appsec1){ref-type="sec"}. GO analysis was performed using Metascape (<http://metascape.org>).[@bib42] The complete GO analysis results can be found in [Supplementary Table 6](#appsec1){ref-type="sec"}.

### LINE-1 pyrosequencing {#sec3.6.3}

DNA extraction from human dermal fibroblasts (3 controls and 3 CAID patients) at p8 and p14 was performed using the QIAamp DNA Mini Kit (51304; Qiagen). Bisulfite conversion was performed as previously described in the RRBS methods section. Bisulfite converted DNA was amplified and enriched for *LINE-1* conservative sequences using specific primers (*LINE-1* forward and *LINE-1* biotinylated reverse primer) designed with PyroMark Assay Design (Qiagen). The primers were designed to allow the coverage of 2 CpG sites. The methylation percentage of *LINE-1* CpG sites was assessed using PyroMark Q24 (Qiagen) pyrosequencing technology ([Table 10](#tbl10){ref-type="table"}).Table 10*LINE-1* Pyrosequencing PrimersPrimerSequenceForward 5'GGGTATAGGGAAGGGAATATTATATATTAGReverse 3'CCATCAACTCACCATCTACATTSequencingAGGGAATATTATATATTAGGGT

### Library preparation and ATAC sequencing {#sec3.6.4}

ATAC sequencing libraries were generated from 100,000 human skin fibroblasts from 3 controls and 3 CAID patients. Cells were lysed with ice-cold hypotonic cell lysis buffer (0.1% wt/vol sodium citrate tribasic dihydrate and 0.1% vol/vol Triton) for 30 minutes on ice followed by a second 30-minute lysis step with ice-cold cell lysis buffer (10 mmol/L Tris-HCl, pH 7.4, 10 mmol/L NaCl, 3 mmol/L MgCl~2~, and 0.1% vol/vol Octylphenoxy poly(ethyleneoxy)ethanol, branched (IGEPAL) CA-630 NON999, Bioshop, Burlington, Ontario, Canada). The transposition reaction was performed in a 25-μL reaction volume using 5 μL tagmentation DNA enzyme in 2× Tagmentation DNA (TD) buffer (FC-121-1030; Illumina). EDTA (25 mmol/L) was added to the reaction mix before DNA recovery with MiniElute PCR Purification columns (28004; Qiagen). Paired-end sequencing of the libraries was performed on a paired-end, 125 pb Illumina Hiseq 2500.

### ATAC sequencing data processing and analysis {#sec3.6.5}

ATAC sequencing reads were trimmed for adapter sequences and low-quality score bases (Phred score \< 20) and were mapped to the human reference genome (GRCh37/hg19). Mapping was performed using Burrows-Wheeler Aligner (BWA-MEM) in (Source Forge, New York, USA) paired-end mode at default parameters.[@bib50] Only reads that were paired properly and had a unique alignment (mapping quality \> 10) were retained. PCR duplicates were removed using Picard tools (<http://broadinstitute.github.io/picard/>). Peaks were first called on ATAC sequencing using the MACS2 (Liu lab, Cambridge, MA) software suite with the added parameters "-g hs -q 0.05 --keep-dup all --broad --nomodel --extsize 200 --nolambda."[@bib51] For comparison between samples, all peaks from each sample were merged to provide 1 set of combined peaks. For quantification of the combined peaks, we used FeatureCount (v1.4.4) to count the number of overlapping reads for each sample.[@bib39] For all downstream analyses, we excluded sex chromosomal or low-count peaks with an average read count lower than 30 across all samples, resulting in 69,249 peaks in total. Chromatin accessibility levels across samples were normalized using the weighted trimmed mean of M values algorithm, implemented in edgeR R package.[@bib40] Afterward, we log-transformed the data and obtained precision-weights using the voom function in the limma package.[@bib41] Finally, we performed a weighted fit, using lmFit (also from limma) and the weights obtained from voom. To interrogate for genotype effects on chromatin accessibility in fibroblasts at passages 8 and 14, we used a nested linear model with the following design: chromatin accessibility ∼ sex + biopsy_age + genotype:passage. Nominal *P* values provided by lmFit were corrected for multiple testing using the Benjamini--Hochberg method. ATAC sequencing mapping statistics and the complete list of differentially methylated regions can be found in [Supplementary Table 7](#appsec1){ref-type="sec"}. Peaks with a log~2~ fold change greater than 1 and less than -1 were considered as more open and less open, respectively. FDR-adjusted *P* value (q value) \< .1 was considered significant. GO analysis was performed using Metascape (<http://metascape.org>).[@bib42] The complete GO analysis results can be found in [Supplementary Table 8](#appsec1){ref-type="sec"}.

Statistical Analyses {#sec3.7}
--------------------

*P* values from RNA sequencing, SILAC, RRBS, and ATAC sequencing experiments were corrected for multiple testing using the Benjamini--Hochberg method (q value). GO analysis *P* values were calculated based on accumulative hypergeometric distribution and corrected for multiple testing using the Benjamini--Hochberg procedure. Reverse-transcription quantitative PCR, Western blot, and *LINE-1* retrotransposons methylation quantification significance was calculated using 1-way analysis of variance with the Bonferroni post-test. Multiple group statistical comparisons (electrophysiology and TGF-β signaling response) were obtained by 2-way analysis of variance with the Bonferroni post-test, and individual group mean differences (electrophysiology) were evaluated by the Student *t* test with Bonferroni correction.

Supplementary Material {#appsec1}
======================

Supplementary Table S1Supplementary Table S2Supplementary Table S3Supplementary Table S4Supplementary Table S5Supplementary Table S6Supplementary Table S7Supplementary Table S8
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[^1]: ECM, extracellular matrix.

[^2]: SMAD, Mothers Against Decapentaplegic Homolog.
